Ex-vivo mucolytic and anti-inflammatory activity of BromAc in tracheal aspirates from COVID-19 - 16/03/22
, Geovane Marques Ferreira a, Alice Aparecida Lourenço a, Ágata Lopes Ribeiro a, Camila Pacheco da Silveira Martins da Mata b, Patrícia de Melo Oliveira a, Daisymara Priscila de Almeida Marques a, Linziane Lopes Ferreira a, Felipe Alves Clarindo a, Murillo Ferreira da Silva c, d, Heitor Portella Póvoas Filho e, Nilson Roberto Ribeiro Oliveira e, Maisah Meyhr D’Carmo Sodré d, Sandra Rocha Gadelha c, d, George Rego Albuquerque d, f, Bianca Mendes Maciel c, d, Ana Paula Melo Mariano c, d, Mylene de Melo Silva d, Renato Fontana c, d, Lauro Juliano Marin d, g, Renata Santiago Alberto Carlos f, Amanda Teixeira Sampaio Lopes d, Fabrício Barbosa Ferreira d, Uener Ribeiro dos Santos c, Íris Terezinha Santos de Santana d, Hllytchaikra Ferraz Fehlberg d, Rachel Passos Rezende c, João Carlos T. Dias c, Eduardo Gross c, Gisele Assis Castro Goulart h, Marie Gabriele Santiago h, Ana Paula Motta Lavigne de Lemos e, Aline O. da Conceição c, Carla Cristina Romano e, Luciana Debortoli de Carvalho c, Olindo Assis Martins Filho i, Claudio Almeida Quadros j, David L. Morris k, l, m, ⁎ , Sarah J. Valle k, l, ⁎
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Abstract |
COVID-19 is a lethal disease caused by the pandemic SARS-CoV-2, which continues to be a public health threat. COVID-19 is principally a respiratory disease and is often associated with sputum retention and cytokine storm, for which there are limited therapeutic options. In this regard, we evaluated the use of BromAc®, a combination of Bromelain and Acetylcysteine (NAC). Both drugs present mucolytic effect and have been studied to treat COVID-19. Therefore, we sought to examine the mucolytic and anti-inflammatory effect of BromAc® in tracheal aspirate samples from critically ill COVID-19 patients requiring mechanical ventilation.
Method |
Tracheal aspirate samples from COVID-19 patients were collected following next of kin consent and mucolysis, rheometry and cytokine analysis using Luminex kit was performed.
Results |
BromAc® displayed a robust mucolytic effect in a dose dependent manner on COVID-19 sputum ex vivo. BromAc® showed anti-inflammatory activity, reducing the action of cytokine storm, chemokines including MIP-1alpha, CXCL8, MIP-1b, MCP-1 and IP-10, and regulatory cytokines IL-5, IL-10, IL-13 IL-1Ra and total reduction for IL-9 compared to NAC alone and control. BromAc® acted on IL-6, demonstrating a reduction in G-CSF and VEGF-D at concentrations of 125 and 250 µg.
Conclusion |
These results indicate robust mucolytic and anti-inflammatory effect of BromAc® ex vivo in tracheal aspirates from critically ill COVID-19 patients, indicating its potential to be further assessed as pharmacological treatment for COVID-19.
El texto completo de este artículo está disponible en PDF.Highlights |
• | BromAc is a strong mucolytic for COVID-19 sputum ex vivo. |
• | Select chemokines and cytokines were downregulated following BromAc exposure. |
• | Mucolytic and anti-inflammatory effects of BromAc were dose-dependent. |
• | Further assessment of BromAc in COVID-19 clinical trials is warranted. |
Keywords : BromAc, COVID-19, Tracheal aspirate, SARS-CoV-2, Mucolytic therapy
Esquema
Vol 148
Artículo 112753- avril 2022 Regresar al número
Artículo precedente
- The dual gastro- and neuroprotective effects of curcumin loaded chitosan nanoparticles against cold restraint stress in rats
- Kholoud A. Ali, Mona M. El-Naa, Alaa F. Bakr, Mohamed Y. Mahmoud, Essam M. Abdelgawad, Mohammed Y. Matoock
- Yiqi Tongluo Fang could preventive and delayed development and formation of diabetic retinopathy through antioxidant and anti-inflammatory effects
- Sha Di, Xuedong An, Bing Pang, Tiange Wang, Haohan Wu, Jia Wang, Min Li
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.